banner news

Singapore, September 20, 2019 – Credo Biomedical Pte. Ltd., a groundbreaking point-of-care rapid molecular diagnostic company, will be featured in the newest episode of Advancements with Ted Danson that will broadcast Nationwide via CNBC on Saturday, September 21st @11:00am ET.

 

The segment will focus on Credo Biomedical’s new molecular diagnostic platform, VitaPCR. Combining speed, accuracy, and ease-of-use required for any advanced POC molecular diagnostic platform, VitaPCR Influenza A/B delivers rapid and actionable results for the same price level as RIDTs, making molecular diagnostic tools highly accessible to patients and affordable to all.

 

“Viewers will learn about Credo Biomedical's POC Real-Time PCR platform, which provides medical professionals with molecular diagnostic results at the point-of-care, to make critical decisions at a cost level traditionally reserved for rapid test.”

 

Advancements with Ted Danson will be aired on CNBC at 11:00am ET on Saturday, September 21st with multiple replays during the following weeks.

 


About Credo Biomedical Pte. Ltd.

Credo Biomedical develops, and manufactures innovative, cost-effective, and rapid Molecular Diagnostic solutions at the Point-of-Care (POC) in the areas of Animal Health, Human Health, and Human Wellness. By providing the right information, at the right time, and to the right people, we can improve the lives of billions of people and animals around the world.

 

 

About Advancements and DMG Productions

The Advancements television series is an information-based educational program, targeting recent advances across a number of industries and economies. Featuring state-of-the-art solutions and important issues facing today's consumers and business professionals, Advancements focuses on cutting-edge developments, and brings this information to the public with the vision to enlighten about how technology and innovation continue to transform our world.

 

 

CONTACT

We at Credo pioneer accessible diagnostic platforms to improve the lives of those we love. We believe providing the right information to the right people at the right time leads to better outcomes.